BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Air Quality Index for one’s region can be a handy thing to know, but it’s such a dry and humorless number, isn’t it? Well, all that changes with [Andrew Kleindolph]’s AQI Funnies: a visual ...

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed ...

BMO Capital raised the firm’s price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The ...

If you need to write up some technical documentation in Microsoft Word, the Consolas font will likely serve you well. This ...

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials ...

The decision to reduce the company's workforce and pause other pipeline activities to focus entirely on COMP360 has been ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...

The Honda Passport was always the most rugged Honda SUV sold in the United States, with more of an off-roading edge than the ...

Prices will start in the mid-$40,000s for the entry-level RTL trim, but take a step up to the TrailSport and you’ll get the ...

These trials are expected to launch in the first half of 2025, with data readouts expected by year-end. With Phase 2 data for UNVEIL-IT trial also anticipated by the close of 2025, GENFIT will deliver ...